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Background: Acute bacterial meningitis (ABM) is a rapidly developing acute inflammation of
leptomeninges and underlying subarachnoid cerebrospinal fluid (CSF). ABM is caused by
bacteria and has a case fatality rate of 20e30%. Most prevalent causes of ABM are Neisseria
meningitis, Streptococcus pneumoniae and Haemophilus influenzae. The aim of this paper is
to summarize the main findings from Cochrane systematic reviews that have considered the
evidence for treatments of ABM.
Methods: We searched the Cochrane Library (issue 1, 2007) for relevant reviews using ‘menin-
gitis’ as a search term. The titles of all the search results were examined to select reviews on
treatment of ABM. The full text of each of the selected reviews was studied to summarize the
evidence available in Cochrane systematic reviews.
Results: We found three Cochrane reviews that focused specifically on the treatment of ABM,
addressing empiric antibiotic therapy, fluid therapy and effects of adjuvant corticosteroids
respectively. No statistically significant difference was found between third generation ceph-
alosporins and conventional antibiotics in the combined endpoint of death or deafness (risk
difference (RD) 1%, 95% CI 4% to þ2%). However, culture positivity of CSF at 10e48 h was
significantly higher in the conventional antibiotic group and diarrhoea was significantly more
common in the cephalosporin group. When third generation cephalosporins are not available,
ampicillinechloramphenicol combination may be used as an alternative empiric treatment,
however both resistance pattern as well as availability should be considered while prescribing
empiric therapy of community acquired ABM. The fluid therapy review found too few studies to
provide any robust conclusion. In settings with high mortality rates and where patients present
late, use of intravenous maintenance fluids seems preferable to a restricted fluid intake. The
efficacy of adjuvant corticosteroids varied between high- and low-income countries suggesting
greater mortality reduction in high-income countries (RR 0.74, 95% CI 0.52e1.05) than in low-
income countries (RR 0.87, 95% CI 0.72e1.05) and a beneficial effect on severe hearing loss in
high-income countries (RR 0.32, 95% CI 0.18e0.57), whereas, sparse data in low-income
countries (RR 1.04, 95% CI 0.66e1.63). A four-day regimen of dexamethasone should be givenrasad, Department of Internal Medicine, College of Medicine & Medical Sciences, Arabian Gulf
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946 K. Prasad et al.preferably before or with the first dose of antibiotics for cases of ABM from high-income
countries.
Conclusion: In presence of sensitive organisms, third generation cephalosporins and conven-
tional antibiotics lead to similar outcomes. More studies are needed to determine the antimi-
crobial resistance pattern against various antibiotics in rural and remote areas of developing as
well as developed countries. To assess the effectiveness of either restricting or maintenance
fluids in populations where patients present early and on death and disability when mortality
rates are low, large trials should be conducted. More trials are needed to assess the use of
adjuvant dexamethasone for ABM in low-income countries.
ª 2009 Elsevier Ltd. All rights reserved.Background
Acute bacterial meningitis (ABM) is rapidly developing
inflammation of leptomeninges (pia-arachnoid) caused by
pyogenic bacteria. Neisseria meningitidis, Streptococcus
pneumoniae, and Haemophilus influenzae account for most
cases of ABM. Despite advances in our knowledge of patho-
physiology of meningitis, antibiotic therapy and improved
critical care, ABM is associated with a case fatality rate of
almost 20e30%, especially in developing countries.1 An
additional 5e40% cases have only partial recovery with
disability sequelae.1 Effective treatment strategies are
required to reduce the mortality and morbidity associated
with ABM.
In this paper, we review the available evidence on
measures for treating ABM. We will restrict ourselves to
interventions that have been subject of Cochrane systematic
reviews, as these reviews make systematic attempts to
synthesize high quality evidence from randomized-
controlled trials (RCTs) and may be considered at the top of
hierarchy of levels of evidence.
Methods
In January 2007, we searched the Cochrane Library (issue 1,
2007) for relevant reviews using ‘meningitis’ as a search
term. The titles of all the search results were examined to
select reviews on treatment of ABM. The full text of each of
the selected reviews was printed out and studied.
Results
The initial search yielded 127 hits. After examining the
titles, we selected three reviews as relevant to the topic; all
the three were focused on treatment of ABM. Table 1
provides a brief summary of these reviews. For each selected
review, we provide below the details of methods and results.
Methods common to all reviews
The three included Cochrane reviews were conducted after
searching the literature in various databases, mainly MED-
LINE, EMBASE and the Cochrane Central Register of
Controlled Trials (central). In addition, reviewers used
other strategies to find relevant studies. The strategies
included searching specialized databases within the
Cochrane Collaboration, such as the Cochrane AirwaysGroup Trials Register or Cochrane Infectious Diseases Group
Trial Register, checking references of relevant articles and
writing to authors for additional studies.
More than one reviewer independently assessed eligi-
bility of the studies for their review, assessed their meth-
odological quality, and extracted the data. All reviewers
used the Cochrane Collaboration software Revman to
synthesize their data.
Cochrane review on third generation
cephalosporins versus conventional antibiotics
for treating acute bacterial meningitis (ABM)
Empirical therapy of suspected ABM is driven by likely path-
ogens, local antibiotic resistance patterns and availability of
medicines. While many physicians continue to use conven-
tional antibiotics (benzylpenicillin, or ampicillin, with or
without chloramphenicol), others have started using third
generation cephalosporins. It is unclear whether there is
difference between the cephalosporins or conventional
antibiotics in terms of clinical outcomes. The objective of the
review was to compare the effectiveness and safety of the
third generation cephalosporins with conventional treat-
ment, i.e. penicillin/ampicillinechloramphenicol in patients
with community-acquired acute bacterial meningitis.
The last search of the literature was carried out in
November 2006. The authors selected RCTs comparing third
generation cephalosporins with conventional antibiotics in
patients with community acquired ABM. The RCTs included
children as well as adults. Ceftriaxone (16 trials) or cefo-
taxime (two) or ceftazidime (one) were compared with
penicillin alone, ampicillinechloramphenicol combination,
penicillinechloramphenicol combination or chloramphen-
icol alone. Death, severe sensorineural deafness, culture
positivity of CSF after 10e48 h and adverse effects of the
drugs were the outcome measures.
Nineteen trials with 1496 participants were included in
the analysis. Ten trials were contributed by developing
countries and nine trials by developed countries. The
reports did not have sufficient details to permit adequate
assessment of methodological quality. No statistically
significant difference was found between third generation
cephalosporins and conventional antibiotics in the inci-
dence of deaths (risk difference [RD] 0%, 95% confidence
interval (95% CI) 3% to þ2%), sensorineural deafness (RD
4%, 95% CI 9% to þ1%), combined endpoint of death or
deafness (RD 1%, 95% CI 4% to þ2%), skin rash (RD 1%,
95% CI 4% to þ2%). However, culture positivity of CSF at
Table 1 Summary of Cochrane Reviews.







Third generation cephalosporins versus
conventional antibiotics for treating
acute bacterial meningitis2
2006 19 No clinically important difference between the use of cefotaxime
and conventional antibiotics. Ampicillinechloramphenicol
combination may be used as an alternative when third generation
cephalosporins are not available.
Fluid therapy for acute bacterial
meningitis3
2005 3 In settings with high mortality rates and where patients present
late, intravenous maintenance fluids are preferred to restricted
intake, in the first 48 h. Insufficient evidence in case of lower
mortality rates and when children present early.
Corticosteroids for acute bacterial
meningitis4
2006 20 Adjuvant corticosteroids are beneficial in treatment of acute
bacterial meningitis in children as well as in adults in high-income
countries.
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biotic group and occurrence of diarrhoeas was significantly
more common in the cephalosporin group. The results of
analysis according to the causative organism did not reveal
any difference between the two regimens, though the
organism-specific data were sparse and power for analysis
with respect to each organism was inadequate.
The authors conclude that there was no clinically impor-
tant difference between ceftriaxone or cefotaxime versus
conventional antibiotics. However, they point out that the
resistance pattern has changed since the publication of trials;
most of which were conducted in the 1980s. Both resistance
pattern as well as availability should be considered while
prescribing empiric therapy for community acquired ABM.
Cochrane review on fluid therapy for acute
bacterial meningitis
Hyponatraemia is present in over 50% of children with
meningitis at the time of admission. It is associated with
adverse neurodevelopmental outcomes.5,6 Opinion varies
on whether the hyponatraemia is due to dehydration or
inappropriate ADH secretion. Accordingly, there is contro-
versy about whether to restrict fluid or to give intravenous
maintenance fluid in early stages of ABM in children.
The objective of this review was to compare the effects
of administration of restricted-versus full-maintenance
fluid volume in the initial 72 h after presentation, on death
and neurological sequelae.
The last search of the literature was carried out in March
2005. The authors included only RCTs. They intended to
include all age groups of patients but the included studies
had only children as subjects.
Only three trials were found eligible. The largest of the
three trials was conducted in Papua New Guinea (Duke,
2002) in settings with high mortality rates.7 The Cochrane
review with 415 children included in the analysis, found no
statistically significant difference between full mainte-
nance fluid and restricted-fluid groups for deaths (risk ratio
(RR) 0.82, 95% CI 0.53e1.27); for acute severe neurological
sequelae (RR 0.67, 95% CI 0.41e1.08); and for mild to
moderate sequelae (RR 1.24, 95% CI 0.58e2.65). However,
all the 95% CIs were wide and did not exclude a clinicallyimportant difference. There was statistically significant
difference in favour of the maintenance-fluid group, in
regard to spasticity (RR 0.50, 95% CI 0.27e0.93), seizures at
both 72 h (RR 0.59, 95% CI 0.42e0.83) and 14 days (RR 0.19,
95% CI 0.04e0.88), and chronic severe neurological
sequelae at 3 months follow up (RR 0.42, 95% CI 0.20e0.89).
The authors conclude that there is some evidence to
support the use of intravenous full maintenance fluid, in
preference to restricted fluid, in the first 48 h in children in
developing country settings (where patients present late
and mortality rates are high). However, there is insufficient
evidence to guide practice in settings where children
present early and mortality rates are low.
Cochrane review on corticosteroids for acute
bacterial meningitis
ABM remains a disease with high mortality and morbidity
despite advances in antibiotic therapy and critical care.
The severity of CSF inflammatory response correlates well
with outcomes1,8,9 Corticosteroids are known to reduce this
inflammation, and hence may improve the outcome. The
objective of this Cochrane review was to evaluate the
effects of adjuvant corticosteroids on mortality, severe
hearing loss and neurological sequelae; in the treatment of
children and adults with ABM.
The last search of the literature was carried out in June
2006. The authors included randomized-controlled trials in
all age groups with any corticosteroid. Twenty trials
involving 2750 patients were included. Dexamethasone was
used in 17 of 20 studies. Overall, adjuvant corticosteroids
were associated with lower case fatality (RR 0.83, 95% CI
0.71e0.99) and lower rates of both hearing loss (RR 0.65,
95% CI 0.47e0.91) and long-term neurological sequelae (RR
0.67, 95% CI 0.45e1.00). However, efficacy of corticoste-
roids varied between high- and low-income countries sug-
gesting greater mortality reduction in high-income
countries 0.74 (95% CI 0.52e1.05) than in low-income
countries 0.87 (95% CI 0.72e1.05). Further, in case of
severe hearing loss, corticosteroids had protective effect in
high-income countries (RR 0.32, 95% CI 0.18e0.57),
whereas, no beneficial effect was seen in low-income
countries (RR 1.04, 95% CI 0.66e1.63).
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corticosteroids before or with the first dose of antibiotics
(RR 0.84. 95% CI 0.70e1.02) as well as after the first dose of
antibiotics (RR 0.80, 95% CI 0.70e1.02).
The resultswere similar across all causativeorganisms. The
authors conclude that in high-income countries, the use of
corticosteroids has beneficial effects showing lower case
fatality in adults with acute bacterial meningitis (RR 0.57, 95%
CI 0.40e0.81) and in children with ABM, (RR 0.99, 95% CI
0.81e1.20). Further, corticosteroids have beneficial effects
on short-term sequelae in adults (RR 0.57, 95% CI 0.40e0.81)
and prevention of hearing loss in children (RR 0.61, 95% CI
0.44e0.86). It is recommended that dexamethasone should
be given to all patients, children as well as adults with ABM in
high-income countries, irrespective of bacterial aetiology and
should be initiated before or with the first dose of antibiotics.
Discussion
The mainstay of treatment of ABM is antibiotics. The anti-
biotic has to be started empirically because culture and
sensitivity reports take 24e48 h.
Recent reviews and textbooks recommend use of
combination of vancomycin and ceftriaxone10e14 instead of
ceftriaxone alone; while many resource-constrained coun-
tries still use conventional antibiotics. The RCT by Nathan
et al.15 suggests that efficacy of single dose treatment with
ceftriaxone is not inferior to that of oily chloramphenicol
for epidemic meningococcal meningitis. The Cochrane
review by Prasad et al.2 provides strong evidence that the
two are of nearly equivalent efficacy, and adopting cef-
triaxone or cefotaxime is completely justified. The trial
report by Nathan et al.,15 further strengthens the case for
ceftriaxone as initial empiric therapy.
Regarding recommendation to combine vancomycin with
ceftriaxone, there is no RCT comparing the combination
with ceftriaxone alone, but there is evidence that cef-
triaxone resistance is more prevalent amongst penicillin-
resistant S. pneumoniae isolates, whereas little or no
resistance was detected to vancomycin (0% intermediate
and resistance).16 Microbiology experts recommend that
when more than 3% of cultures show resistance to an
antibiotic, another antibiotic should be added.
A critical question is: what evidence do we need to
recommend an empiric antibiotic or combination of anti-
biotics? Should it be only the evidence of sensitivity or
resistance in laboratory isolates for CSF; or should it also
require RCTs to make evidence-based recommendation. It
seems logical to use combination when resistance is
detected in laboratories and the resistance correlates with
unfavorable outcome in the patients. To demand RCTs in
this situation may entail avoidable risks to human life, but
at least there should be local evidence of resistance and
documented correlation with outcome. However, it is quite
legitimate to ask evidence from RCTs considering that all
RCTs involving serious illness are associated with risk of
death and/or disability. The only difference may be that in
meningitis, we deal with a clearly identifiable cause and
laboratories provide reliable evidence of how the organisms
might respond to the intervention.
Undoubtedly, when there is no unacceptably high
frequency of resistance, then adoption of a new antibioticrequires evidence from RCTs comparing old and new anti-
biotic regimens such as vancomycin plus ceftriaxone versus
ceftriaxone alone. There are no Cochrane reviews of such
RCTs, and there is a need to do this if they exist. Probably,
the new antibiotics become standard therapies soon after
the first or second RCTs and reviewers may not find it
worthwhile to conduct the reviews on widely accepted
interventions. Yet, these reviews may be important as they
provide insights not available from single RCTs.
Fluid therapy is an important issue in the treatment of
bacterial meningitis, especially in children. The three
studies included in the Cochrane review on the topic have
been conducted in developing countries, where patients
often reach late and have dehydration. This may be the
reason why maintenance therapy is associated with better
outcome than fluid restriction. Though the authors pre-
sented completely separate analysis for deaths, mild/
moderate and severe neurological sequelae, assessed within
four weeks (short-term), we think this may be misleading.
An intervention that causes more deaths may leave less
people with sequelae and hence may appear better when
sequelae are analyzed alone. For a valid perspective, anal-
ysis of combined outcome of death and sequelae is neces-
sary. We performed this and obtained a combined risk ratio
of 0.72 (95% CI 0.48e1.07). Although not statistically
significant, it shows a moderately strong trend in favour of
maintenance fluid. In the light of statistically significant
findings for other outcomes, such as reduced spasticity,
seizures and long-term neurological sequelae, maintenance
fluid therapy should be used. There are two caveats: one,
whether the results apply to developed countries is difficult
to assess, as clinical outcomes are available for only two
studies conducted in developing countries (Papua New
Guinea and India). Second, the findings cannot be described
as robust because the total number of patients in the
Cochrane review is only 415. For both these reasons, more
studies are indicated, particularly from developed coun-
tries. Until contrary results appear in the literature, a safe
recommendation may be to use maintenance fluid therapy
in patients with acute bacterial meningitis.
The burden of mortality and morbidity due to ABM
continues to remain high despite antibiotics. Adjuvant
therapies are necessary to reduce the burden. As inflam-
mation and its effects form the principal pathophysiological
basis for the adverse outcomes associated with meningitis,
corticosteroids have the potential to improve outcome
through their well established anti-inflammatory effects.
On the basis of evidence from the Cochrane review, corti-
costeroids are effective adjuvants and are recommended to
be given before or with the first dose of antibiotics. The
efficacy of corticosteroids varies between high-income and
low-income countries and is more in case of high-income
countries. Possible reasons for the variation may include:
better infrastructure in high income countries, which
allows for early administration of both antibiotics and
corticosteroids; difficulty in differential diagnosis between
bacterial and tubercular meningitis, and associated
malnutrition in low-income countries which may accen-
tuate the harms with corticosteroids; late diagnosis (where
children present late) is also responsible for low efficacy of
corticosteroids as adjuvants. It is unlikely that any genetic
or pathophysiologic basis explains the difference. Other
Research directions
- Studies are needed to determine the antimicrobial
resistance pattern against various antibiotics in rural
and remote areas of developing as well as developed
countries. More studies are needed to evaluate
whether newer recommended regimens are superior
to those already in practice.
- Large trials are needed to assess the effectiveness of
either restricting or maintenance fluids in pop-
ulations where patients present early and mortality
rates are low.
- RCTs are required for evaluating corticosteroids in
neonatal meningitis. Trials are needed to assess the
use of adjuvant dexamethasone in adults with ABM
in low-income countries. A meta-analysis of indi-
vidual patient data is needed to define the reasons
for differing outcomes in high- versus low-income
countries.
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tory agents have not yet been the subject of a systematic
review. There may not be many RCTs of non-steroidal anti-
inflammatory agents yet but still a systematic review may
identify issues that need to be addressed for further RCTs.
Besides those indicated above, other potential targets
for treatment of bacterial meningitis include agents inhib-
iting cytokines, anti-inflammatory cytokines like IL-10 or
TGF-beta, targeted inhibition of NF-kB signaling pathway
regulating cytokines, anti-leukocyte agents, and vascular
endothelium growth factor acting on the blood-brain
barrier. If some of these strategies could stop the
progression of pathophysiologic cascade, they may poten-
tially improve the neurological outcome and advance our
ability to effectively treat patients with acute bacterial
meningitis. The role of prophylactic and routine use of anti-
convulsants in all patients or specific groups, such as chil-
dren or those with pneumoccocal disease, is also unclear
and needs to be addressed in future studies.
Conclusions
Cochrane systematic review suggests that third generation
cephalosporins, usually ceftriaxone, and ampicilline
chloramphenicol combinations are equivalent alternatives
to start initial empiric treatments in acute bacterial
meningitis to conventional therapies. In settings with high
mortality rates and where patients present late, intrave-
nous maintenance fluids are preferred to a restricted fluid
intake in the first 48 h. Adjuvant corticosteroids are bene-
ficial in treatment of acute bacterial meningitis in adults
and in children from high-income countries with good
access to services. Yet to be established is efficacy of this
approach in developing countries. Based on studies in the
Cochrane systematic review, the reviewers recommended
a four-day regimen of dexamethasone, given preferably
before or with the first dose of antibiotics, in all age groups.
Meta-analysis of individual patient data would be
required to define the reasons for differing outcomes in
high- versus low-income countries.Practice points
- Ampicillinechloramphenicol combination may still
be used as an initial empiric treatment in acute
bacterial meningitis when third generation cepha-
losporins are not available and the locally isolated
bacteria do not show significant resistance.
- Intravenous maintenance fluids are preferred to
restricted fluid intake in the first 48 h, in settings
with high mortality rates and where patients present
late.
- Adjuvant Corticosteroids are beneficial in treatment
of acute bacterial meningitis in children as well as
adults from high-income countries with good access
to services. Therefore a four-day regimen of dexa-
methasone can be given preferably before or with
the first dose of antibiotics, in high-income
countries.Conflict of interest
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